AxisPharm provides high-purity PROTAC PEG linkers and reagents with various active groups, such as azide, acid, amine, etc.
The design of Proteolysis Targeting Chimera (PROTACs) is a powerful small molecule approach for inducing protein degradation for anticancer therapy. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. To further empower the PROTAC study, AxisPharm is developing a series of PROTAC linkers to accelerate our customers’ R&D efforts.
![l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lHpyrazolo [3,4-d]pyrimidin-l-yl]-l-piperidinyl]-2-propyn-l-one](https://axispharm.com/wp-content/uploads/AP14272-CAS-936563-91-6-1-e1686054563587.png)
![N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine](https://axispharm.com/wp-content/uploads/AP14270-CAS-231278-20-9-1-e1686064939791.png)
![3-{5,7-dioxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-6-yl}piperidine-2,6-dione](https://axispharm.com/wp-content/uploads/AP13955-CAS-31804-66-7-1.png)
